Pharma Partners seeks to identify what motivates our candidates, whether they are looking for the excitement and agility of a biotech or a smaller pharmaceutical company, or instead are looking to join an established global player. We ensure the identification, attraction and presentation of the right talent who will add value to the industry.
LATEST JOBS
-
Senior Brand Manager - Consumer Healthcare
Permanent / South West England, England
Senior Brand Manager Consumer Healthcare Our client is a leading international healthcare business with a global range of both consumer and prescription products. They have a global presence, including ten offices and an extensive distributor network covering over 100 countries. Their UK business has been recognised as a Great Place To Work two years in a row. They are recruiting a Senior Brand Manager for their Consumer Healthcare team due to internal progression & growth. Key Responsibilities Maximise sales via creation & implementation of strategic & tactical marketing plans Manage brand lifecycle & develop value propositions to engage patients, retail buyers, and HCPs Use market research to explore new growth opportunities Work with external agencies Ensure all marketing messages are fully compliant and accurate Person Specification At least 3 years' experience in similar brand/marketing role Healthcare, pharmaceutical, nutrition or FMCG experience Strong digital marketing capabilities Demonstrable success in growing established brands Creativity & 'can do' attitude To apply for this position or find out about similar opportunities then please contact Lois Kelly via Lois.kelly@pharma-partners.co.uk
details
-
Director - RWE Strategy & Partnerships (Global Med Affairs)
Permanent / Massachusetts, USA
Director - RWE Strategy & Partnerships (Global Medical Affairs) As part of the Global Medical Affairs group, this position reports into the VP & Head of Data Insights/Generation and sits alongside counterparts for Epidemiology and Biostatistics. This position is responsible for collaborating with different business functions to align product RWE strategy as part of an integrated evidence generation plan. You will need to develop RWE programs that resolve any evidence gaps across the portfolio/pipeline. You will need to develop and maintain strong external partnerships to utilise existing and emerging sources of Real World Data, and identify new technologies and opportunities to advance the businesses evidence generating capabilities. Key responsibilities: Design and implement a strategic RWE framework Develop RWE programs to bridge evidence gaps Identify opportunities to partner with key external data sources Seek out and attend relevant conferences and events Create therapy area specific RWE plans Design, implement, and oversee all RWE programs Collaborate cross functionally with key internal stakeholders on RWE projects Ensure global alignment of Medical Affairs studies Devise and implement an RWE framework Candidate Requirements: Scientific qualification, ideally to post-graduate degree level (eg. MSc, PhD, MD, MPharm) Demonstrable experience in RWE (must be from Pharma and not solely agency) Experience of working in Medical Affairs Ability to develop and maintain key internal and external relationships Curiosity and passion for advancing technologies and science Excellent communication skills Salary & Remuneration: Annual salary depending on location and experience plus a benefits package to include car allowance and annual bonus To apply for this position please use the "Easy Apply" option or feel free to send your CV directly to the Pharma-Partners team via email info@pharma-partners.co.uk
details
-
Senior Regulatory Affairs Manager - Global Rare Disease
Permanent / Buckinghamshire, England
Job title: Senior Regulatory Affairs Manager - Global Rare Disease A growing Rare Disease Biotech based in Buckinghamshire are seeking a Senior Regulatory Affairs Manager. This is a global role focused on an initial three markets - Israel, Turkey and Switzerland. In this role you will work cross-functionally and with external partners to develop and execute regulatory strategies to gain approval and then maintain marketing authorisations. This role is office-based 1 day per week. Responsibilities: Preparation and submission of high-quality regulatory applications in Eastern Europe, Middle East and African Markets, including preapproval applications (paediatric, Orphan Drug, scientific advice), marketing authorisations submissions. Effectively partner with other members of Global Regulatory Affairs, cross-functional stakeholders, and external partners to deliver the regulatory contribution of business goals and objectives for the region. Establish and maintain strong and effective relationships with Regulatory Agencies, CROs, and local partners. Contribute and lead initiatives to develop and implement process and system improvements to improve the efficiency of the Global Regulatory Affairs organisation. Requirements: Bachelors or Master's Degree in a scientific discipline or equivalent is required Relevant level of regulatory experience respectively within the pharmaceutical or biotechnology industry. Experience in developing and executing creative regulatory strategies for rare diseases including marketing applications and post approval applications in Eastern Europe, Middle East and Africa, Asia, or Latin America is required. Experience in preparing regulatory applications and developing regulatory strategies for Europe and Switzerland is also beneficial. Must have a solid understanding of global regulations and ICH guidance, as well as comprehensive experience in the drug development process. Experience working in an external development business model in collaboration with strategic local partners and distributors. Salary and benefits: A highly competitive salary, annual bonus and equity is on offer with this role. To apply for this position or hear further details then please contact Matt Thomas via matt.thomas@pharma-partners.co.uk
details
-
Senior Medical Advisor - Gastro
Permanent / London, England
Senior Medical Advisor - Gastro Pharma-Partners is working with a leading and large pharmaceutical business with marketed and pipeline drugs across a range of therapeutic areas. The Senior Medical Advisor will be heavily involved in leading medical affairs projects for our clients' blockbuster Gastro drug. This will include delivering activities in the areas of insight gathering, medical education, scientific communication and real-world evidence generation. The drug has a number of marketed uses in the UK and there is a considerable amount of ongoing research for new indications at PIII. Being part of such a major brand team you will be required to work closely and collaboratively with a large Marketing group. This role reports into the disease area Medical Director and is part of a team of 7. It's worth noting that this position can be recruited at Medical Advisor level and Final Signatory training offered. At this level candidates must already have at least 1 year of UK Medical/Scientific Advisor experience. Key responsibilities: Lead the delivery of the medical plan and tactics Input into medical and disease area strategy Provide scientific and medical expertise to colleagues in Medical Affairs, Marketing, and Commercial groups Integral part of the cross functional brand team Collaborate with clinical operations on delivery of key clinical trials in the UK Lead on insight gathering and real-world evidence generation projects Support Market Access with HTA submissions Provide internal training Establish and maintain relationships with KOLs Review and approve materials in line with the ABPI Code of Practice (training to become a Final Signatory if not already) Represent the business and engage with therapeutic leaders at all relevant major international conferences Candidate Requirements: Medical or Pharmacy degree with appropriate UK registration UK Medical Advisor experience (or equivalent role) Final Signatory status is highly desirable but candidates can be trained Experience in Immunology preferred but not essential Effective in communicating and stakeholder management Salary & Remuneration: Competitive basic annual salary plus a benefits package to include company car/car allowance and yearly bonus To apply for this position please use the "Easy Apply" option or feel free to send your CV directly to the Pharma-Partners team via email info@pharma-partners.co.uk
details
REGISTER with us
We’d like to get to know you.
Click the link below to register with us.
Your journey starts here.
UPLOAD YOUR CV
Already registered?
Complete your profile and upload your CV today.
NEWS
&
SOCIAL
How CRISPR Is Revolutionising Drug Discovery And Medicine
The science behind CRISPR is both fascinating and controversial. A powerful biotechnology tool that gives scientists unprecedented access to the genetic makeup of all living organisms including humans, it originally evolved as an adaptive immune system in bacteria to defend against viruses. When harnessed in the laboratory, however, it allows scientists to edit genes with remarkable accuracy, almost like a pair of scissors that can cut through DNA strands. The technology has already been used to treat diabetes and muscular dystrophy in mice, and in 2020 was used on humans for the first time in a landmark clinical trial to treat a rare condition that causes blindness. It’s easy to see, then, why the medical and scientific community are fascinated by the potential that CRISPR technology has to revolutionise the drug discovery process, and herald a whole new era for human health. How does CRISPR work? CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. These ‘repeats’ are located within bacteria’s DNA, and are actual copies of small pieces of viruses. Bacteria use these copies to identify harmful viruses, and send out the Cas9 enzyme in response to chop them up, mitigating the threat. Having studied this process in depth, researchers in the lab are using a similar approach to turn the microbe’s virus-fighting system into a scientific tool that can quickly and efficiently tweak almost any gene in any plant or animal. Although CRISPR is not the first method available to scientists to alter DNA, it is by far the easiest to use, slashing research time as well as costs. CRISPR is also completely customisable; it can edit virtually any segment of DNA within the 3 billion letters of the human genome with a high degree of accuracy. How can CRISPR impact drug discovery and development? The route to market for any drug is long, costly, and uncertain. In the US, the testing and discovery of any new medication takes more than a decade, with an associated cost that could be upwards of $1 billion. Added to this, the chances of a new drug reaching market is only one in 5,000. This is because all new drugs need to generate satisfactory safety and efficacy data, as well as meet various criteria to be granted marketing authorisation. In the UK, this process is even more complex; drug companies need the National Institute of Health and Care Excellence to recommend that their medication should be available on the NHS, which involves yet another round of cost-benefit analyses that sees many medications rejected at the final hurdle. All of this can be very frustrating for researchers, as well as patients suffering from conditions difficult to treat with standard therapeutics. Another complication for medical researchers is that diseases which arise from genetic mutations, such as cancer and cystic fibrosis, are notoriously difficult to treat. CRISPR, however, is beginning to herald a new era in which future drugs may become safer, cheaper, and drastically more effective. Here are some of the ways this technology is making an impact. Exploring the genetic basis for poorly understood diseases For decades, scientists considered the 98% of our DNA that does not encode for proteins to be inconsequential for drug development. However, we’re increasingly beginning to realise that this so-called ‘dark matter of the genome’ may be more important than previously thought, and actually possess regulatory functions that contribute to disease. Identifying singular, rare mutations that cause devastating genetic conditions such as muscular dystrophy has proved relatively straightforward for scientists, but when it comes to understanding diseases that merely carry a genetically inherited risk with a possible environmental trigger, the story is much more complicated – and this dark matter may hold the key to our understanding. A research team at Duke University are currently exploring this concept by utilising the CRISPR/Cas9 tool to explore the previously poorly understood 98% of the human genome to map out and understand the role it may play in disease development, thus paving the way for treatments that target parts of this genetic material. Helping to make drugs safer Establishing the safety and efficacy of any drug involves a great deal of testing. For ethical reasons, however, initial testing not performed on people. Instead, prior to clinical trials, scientists try to mimic the impact of drugs on crucial tissues, such as the liver and heart, by testing in cell lines and animal models, ensuring that only drugs that pass these tests are escalated to trials in human patients. However, sometimes drugs will show promise when tested on monkeys or mice - as well as in human clinical trials consisting of a few thousand people - yet fail to work as effectively or even cause harmful side effects when used widely. One example of this is the anti-inflammatory drug given the brand name Vioxx, which unfortunately caused thousands of heart attacks despite having previously seemed extremely safe in animal as well as human trials. CRISPR technologies eliminate this issue by enabling researchers to build much more sophisticated cellular models that will more accurately reflect how humans will respond to a new medication. For example, it’s crucial to study how cells absorb, distribute, metabolise and excrete drugs, and part of this work includes identifying the metabolic enzymes of receptors responsible for these actions. This feat can be achieved by generating ‘genetic knockouts’ of enzymes and receptors, something CRISPR technology is optimised for. Improving existing therapies Certain treatments, such as those targeted towards certain forms of cancer, already rely on therapies involving genetic modification. One example of this is CAR-T therapy, which a complex type of immunotherapy sometimes used to treat leukaemia and lymphoma. This type of therapy genetically engineers certain cells to express a receptor that recognises, targets, and destroys cancer. Essentially, CAR-T therapy gives the body a helping hand by making T cells perform their job more effectively. However, generating the required cells using standard genome engineering technologies can be cumbersome and complicated, not to mention costly. CRISPR has enabled researchers to engineer long CAR sequences more efficiently, and has also been proven to boost safety and efficacy. It has also provided the ability to generate multiple gene edits in T cells, a feat that has historically been challenging. Aside from CAR-T, researchers believe that CRISPR could hold the key to developing other effective treatments for cancer, too. The technique is already enabling scientists to gain a deeper understanding of how the disease metastasises, currently a critical gap in knowledge that limits the treatment options available for patients at the advanced stages of the disease. What does the future hold for CRISPR in medicine? Clinical trials are currently underway using CRISPR to treat a whole range of diseases, from rare and devastating disorders such as transthyretin amyloidosis, to more common conditions such as sickle cell anaemia, which impacts one in every 2000 live births in England. Despite its vast therapeutic potential, however, it’s important to bear in mind that the technology does have its limitations. Although it’s useful for deleting problematic genes, it's less effective at replacing them, meaning that only certain inherited conditions can be treated this way. In addition, scientists still have other issues to iron out, such as the potential for unintended consequences known as ‘off-target’ modifications; mutations that are simultaneously created elsewhere in the genome that may have unknown implications. In the summer of 2018 three papers were published raising concerns about such off-target effects, which noted that cells which had successfully been edited using CRISPR turned out to have a defective p53 gene, which may have the potential to cause cancer. Although such unforeseen consequences may be worth it for patients suffering from life-threatening conditions, the impact of such treatments for patients with less serious disorders falls within a much greyer area of medical ethics. In addition, controversies still surround other potential applications of CRISPR technology. Critics worry that the technique could one day be used to enhance normal human traits such as appearance or athletic ability, for example. In 2018, further ethical questions were raised when rogue Chinese researcher He Jianku claimed to have implanted CRISPR-Cas9 gene edited embryos into six women, resulting in at least one successful twin pregnancy, leaping precariously into an era in which science could rewrite the gene pool of future generations. It’s clear, then, that as science discovers incredible new ways to take control of its own evolution, humanity must also learn to wield such power with reason, responsibility, and restraint. Our Pharma Partners team are experts in life science recruitment, and specialise in pharmaceutical physicians, medical affairs, R&D, and the pharmacovigilance space. You can take a look at all our roles here, or get in touch with us for a confidential discussion.